title: Phase separation of an IgG1 antibody solution under a low ionic strength condition.
abstract: OBJECTIVE
  Phase separation of monoclonal antibody A (MAb A) solution and its relation to protein self-association are studied.
  
  
  METHODS
  A phase diagram of MAb A and its dependence on ionic strength and pH were investigated. The protein self-associations were characterized by dynamic light scattering (DLS), analytical ultracentrifugation analysis (AUC) and viscosity measurement.
  
  
  RESULTS
  MAb A solution with a clear appearance in an isotonic ionic strength condition turned opalescent in a low ionic strength condition, followed by liquid-liquid phase separation (LLPS) into light and heavy phases. The protein concentrations of the two phases were dependent on the ionic strength and pH. The two phases became reversibly miscible when the ionic strength or temperature was increased. DLS and AUC showed that MAb A under a low ionic strength condition self-associates at a protein concentration above the critical concentration of 16.5 mg/mL. The viscosity of the heavy phase was high and dependent on the shear rate. These results indicate that attractive protein-protein interaction in the heavy phase induces LLPS.
  
  
  CONCLUSIONS
  LLPS was induced in MAb A solution in a low ionic strength condition due to reversible protein self-association mediated mainly by attractive electrostatic interaction among the MAb A molecules in the heavy phase.
authors.affiliation: Formulation Technology Research Laboratories, Daiichi Sankyo Co., Ltd., 1-12-1 Shinomiya, Hiratsuka, Kanagawa, 254-0014, Japan.
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Nishi
authors.forename: Makoto
authors.initials: M
authors.lastname: Miyajima
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Nakagami
authors.forename: Masanori
authors.initials: M
authors.lastname: Noda
authors.forename: Susumu
authors.initials: S
authors.lastname: Uchiyama
authors.forename: Kiichi
authors.initials: K
authors.lastname: Fukui
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry*; D045744:Cell Line, Tumor; D004797:Enzyme-Linked Immunosorbent Assay; D006863:Hydrogen-Ion Concentration; D007074:Immunoglobulin G / Q000737:chemistry*; D051379:Mice; D009994:Osmolar Concentration; D019999:Pharmaceutical Solutions / Q000737:chemistry*; D044367:Phase Transition; D014783:Viscosity
chemical_list: D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D019999:Pharmaceutical Solutions
references.citation: Acta Crystallogr D Biol Crystallogr. 1994 Jul 1;50(Pt 4):361-5
references.pmid: 15299385
references.citation: J Pharm Sci. 2007 Dec;96(12):3181-95
references.pmid: 17588261
references.citation: Methods Enzymol. 1997;276:100-110
references.pmid: 27799086
references.citation: Biophys J. 2007 Jan 1;92(1):234-44
references.pmid: 17028129
references.citation: Biochim Biophys Acta. 2007 Jan;1774(1):146-53
references.pmid: 17142116
references.citation: Int J Pharm. 2008 Jun 24;358(1-2):1-15
references.pmid: 18485634
references.citation: J Pharm Sci. 2009 Sep;98(9):3043-57
references.pmid: 18823016
references.citation: J Pharm Sci. 2005 Jun;94(6):1161-8
references.pmid: 15858846
references.citation: Pharm Res. 2009 Dec;26(12):2607-18
references.pmid: 19795191
references.citation: Proc Natl Acad Sci U S A. 1987 Oct;84(20):7079-83
references.pmid: 3478681
references.citation: J Pharm Sci. 2010 Jan;99(1):82-93
references.pmid: 19475558
references.citation: J Mol Biol. 2000 Jan 14;295(2):213-24
references.pmid: 10623521
references.citation: J Pharm Sci. 2009 Sep;98(9):3108-16
references.pmid: 19025898
references.citation: J Pharm Sci. 2006 Sep;95(9):1967-83
references.pmid: 16847932
references.citation: Biotechnol Bioeng. 2009 Mar 1;102(4):1141-51
references.pmid: 19031425
references.citation: J Pharm Sci. 2008 Oct;97(10):4219-27
references.pmid: 18240303
references.citation: Biotechnol Bioeng. 2006 Dec 5;95(5):911-8
references.pmid: 16804945
references.citation: Biophys J. 2000 Mar;78(3):1606-19
references.pmid: 10692345
references.citation: J Pharm Sci. 2010 Mar;99(3):1152-68
references.pmid: 19705420
references.citation: Proteomics. 2006 Jul;6(13):3958-60
references.pmid: 16718732
references.citation: Science. 1977 Sep 2;197(4307):1010-2
references.pmid: 887936
references.citation: Biochemistry. 2007 Jul 17;46(28):8373-8
references.pmid: 17590018
references.citation: Biol Pharm Bull. 2002 Dec;25(12):1537-45
references.pmid: 12499636
references.citation: Nature. 2004 Nov 25;432(7016):492-5
references.pmid: 15565151
references.citation: Methods Enzymol. 1998;295:127-49
references.pmid: 9750217
references.citation: Pharm Res. 1997 Oct;14(10):1472-8
references.pmid: 9358564
references.citation: Crit Rev Ther Drug Carrier Syst. 1993;10(4):307-77
references.pmid: 8124728
references.citation: Int Rev Cytol. 2000;192:171-87
references.pmid: 10553279
references.citation: Pharm Res. 2004 Jul;21(7):1087-93
references.pmid: 15290846
references.citation: Anal Biochem. 2007 Aug 15;367(2):225-37
references.pmid: 17548043
references.citation: Biophys J. 2008 Jan 15;94(2):570-83
references.pmid: 18160663
references.citation: AAPS J. 2006 Sep 22;8(3):E580-9
references.pmid: 17025276
references.citation: Mol Immunol. 2004 Nov;41(12):1211-5
references.pmid: 15482856
references.citation: Biophys J. 2003 Jan;84(1):523-32
references.pmid: 12524304
references.citation: Pharm Res. 2004 Jun;21(6):897-903
references.pmid: 15212151
references.citation: J Pharm Sci. 2005 Sep;94(9):1928-40
references.pmid: 16052543
references.citation: Mol Immunol. 2009 Dec;47(2-3):357-64
references.pmid: 19800690
references.citation: Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14165-70
references.pmid: 12391331
references.citation: Biophys J. 2007 Jul 15;93(2):610-9
references.pmid: 17449660
references.citation: J Pharm Sci. 2004 Jun;93(6):1390-402
references.pmid: 15124199